One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus.
Stefano RadelliniEnrica VigneriValentina GuarnottaFelicia PantoCarla GiordanoPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
Dapagliflozin treatment significantly reduced surrogate indexes of insulin resistance and adiposity in patients with T2D.